Ironwood Pharmaceuticals Inc (IRWD) stock
IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3063% below fair value
$4.87+0.02 (+0.41%)
Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –
Ironwood Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ironwood Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $234.17M, up 219.3% year over year. For fiscal 2025 it was $98.50M, up 5.8% from the year before. The highest annual figure on record is $250.34M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.50M | +5.8% |
| FY2024 | Dec 31, 2024 | $93.12M | – |
| FY2023 | Dec 31, 2023 | -$945.43M | -477.7% |
| FY2022 | Dec 31, 2022 | $250.34M | +7.8% |
| FY2021 | Dec 31, 2021 | $232.26M | +62.5% |
| FY2020 | Dec 31, 2020 | $142.94M | +19.0% |
| FY2019 | Dec 31, 2019 | $120.12M | – |
| FY2018 | Dec 31, 2018 | -$150.67M | – |
| FY2017 | Dec 31, 2017 | -$15.36M | – |
| FY2016 | Dec 31, 2016 | -$51.87M | – |
| FY2015 | Dec 31, 2015 | -$102.09M | – |
| FY2014 | Dec 31, 2014 | -$169.37M | – |
| FY2013 | Dec 31, 2013 | -$252.00M | – |
| FY2012 | Dec 31, 2012 | -$72.76M | – |
| FY2011 | Dec 31, 2011 | -$66.14M | – |
| FY2010 | Dec 31, 2010 | -$60.77M | – |
| FY2009 | Dec 31, 2009 | -$60.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $79.31M | +75.0% |
| Q1 FY2026 | Mar 31, 2026 | $72.57M | – |
| Q4 FY2025 | Dec 31, 2025 | $6.81M | -78.4% |
| Q3 FY2025 | Sep 30, 2025 | $75.48M | +194.4% |
| Q2 FY2025 | Jun 30, 2025 | $45.32M | +81.5% |
| Q1 FY2025 | Mar 31, 2025 | -$29.11M | -364.1% |
| Q4 FY2024 | Dec 31, 2024 | $31.49M | -16.2% |
| Q3 FY2024 | Sep 30, 2024 | $25.64M | -35.9% |
| Q2 FY2024 | Jun 30, 2024 | $24.98M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.02M | -81.7% |
| Q4 FY2023 | Dec 31, 2023 | $37.59M | -45.0% |
| Q3 FY2023 | Sep 30, 2023 | $40.02M | -41.5% |
| Q2 FY2023 | Jun 30, 2023 | -$1.08B | -2046.2% |
| Q1 FY2023 | Mar 31, 2023 | $60.10M | +3.9% |
| Q4 FY2022 | Dec 31, 2022 | $68.36M | +20.8% |
| Q3 FY2022 | Sep 30, 2022 | $68.47M | +5.1% |
| Q2 FY2022 | Jun 30, 2022 | $55.66M | -14.5% |
| Q1 FY2022 | Mar 31, 2022 | $57.85M | +27.4% |
| Q4 FY2021 | Dec 31, 2021 | $56.59M | +10.1% |
| Q3 FY2021 | Sep 30, 2021 | $65.17M | +42.9% |
| Q2 FY2021 | Jun 30, 2021 | $65.10M | +99.0% |
| Q1 FY2021 | Mar 31, 2021 | $45.40M | +243.2% |
| Q4 FY2020 | Dec 31, 2020 | $51.38M | +3.6% |
| Q3 FY2020 | Sep 30, 2020 | $45.62M | -30.8% |
| Q2 FY2020 | Jun 30, 2020 | $32.71M | +51.6% |
| Q1 FY2020 | Mar 31, 2020 | $13.23M | – |
| Q4 FY2019 | Dec 31, 2019 | $49.59M | +66.1% |
| Q3 FY2019 | Sep 30, 2019 | $65.89M | – |
| Q2 FY2019 | Jun 30, 2019 | $21.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.93M | – |
| Q4 FY2018 | Dec 31, 2018 | $29.86M | -64.8% |
| Q3 FY2018 | Sep 30, 2018 | -$146.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.68M | – |
| Q1 FY2018 | Mar 31, 2018 | -$35.87M | – |
| Q4 FY2017 | Dec 31, 2017 | $84.79M | – |
| Q3 FY2017 | Sep 30, 2017 | -$19.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$41.01M | – |
| Q1 FY2017 | Mar 31, 2017 | -$39.71M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.30M | – |
| Q3 FY2016 | Sep 30, 2016 | -$28.29M | – |
See a number that looks wrong?